HOXA9 and glioblastoma: Importantly, in the TCGA dataset, 87% of the HOXA9-high GBM patients also display high levels of BCL2, emphasizing that the link between HOXA9 and BCL2 is not only present in in vitro and in vivo models of GBM, but is also relevant in the clinical setting.